During the last session, MEI Pharma Inc. (NASDAQ:MEIP)’s traded shares were 3.67 million, with the beta value of the company hitting 1.26. At the end of the trading day, the stock’s price was $0.50, reflecting an intraday loss of -1.88% or -$0.01. The 52-week high for the MEIP share is $3.56, that puts it down -612.0 from that peak though still a striking 4.0% gain since the share price plummeted to a 52-week low of $0.48. The company’s market capitalization is $64.33M, and the average trade volume was 6.03 million shares over the past three months.
MEI Pharma Inc. (MEIP) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 1.80. MEIP has a Sell rating from 0 analyst(s) out of 10 analysts who have looked at this stock. 4 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.2.
MEI Pharma Inc. (NASDAQ:MEIP) trade information
MEI Pharma Inc. (MEIP) registered a -1.88% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.88% in intraday trading to $0.50 this Thursday, 05/12/22, hitting a weekly high. The stock’s 5-day price performance is -11.86%, and it has moved by -20.00% in 30 days. Based on these gigs, the overall price performance for the year is -80.64%.
The consensus price target of analysts on Wall Street is $5.30, which implies an increase of 90.57% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1.00 and $15.00 respectively. As a result, MEIP is trading at a discount of -2900.0% off the target high and -100.0% off the low.
MEI Pharma Inc. (MEIP) estimates and forecasts
Statistics show that MEI Pharma Inc. has outperformed its competitors in share price, compared to the industry in which it operates. MEI Pharma Inc. (MEIP) shares have gone down -83.20% during the last six months, with a year-to-date growth rate more than the industry average at 40.48% against 9.70. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -100.00% this quarter and then jump 28.60% in the quarter after that. In the rating firms’ projections, revenue will increase 37.00% compared to the previous financial year.
Revenue for the current quarter is expected to be $3.67 million as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to $5.55 million by the end of Mar 2022.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 5.80%. While earnings are projected to return 11.00% in 2022, the next five years will return -0.10% per annum.
MEI Pharma Inc. is due to release its next quarterly earnings between February 02 and February 07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
MEI Pharma Inc. (NASDAQ:MEIP)’s Major holders
MEI Pharma Inc. insiders own 0.57% of total outstanding shares while institutional holders control 71.18%, with the float percentage being 71.59%. BioImpact Capital LLC is the largest shareholder of the company, while 145 institutions own stock in it. As of Sep 29, 2021, the company held over 12.49 million shares (or 11.08% of all shares), a total value of $34.48 million in shares.
The next largest institutional holding, with 8.64 million shares, is of First Light Asset Management, LLC’s that is approximately 7.66% of outstanding shares. At the market price on Sep 29, 2021, these shares were valued at $23.84 million.
Also, the Mutual Funds coming in first place with the largest holdings of MEI Pharma Inc. (MEIP) shares are Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund. Data provided on Sep 29, 2021 indicates that Wasatch Ultra Growth Fund owns about 4.19 million shares. This amounts to just over 3.72 percent of the company’s overall shares, with a $11.57 million market value. The same data shows that the other fund manager holds slightly less at 3.2 million, or about 2.84% of the stock, which is worth about $8.83 million.